Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sight Sciences ( (SGHT) ) has issued an update.
On April 22, 2026, Sight Sciences reported that the U.S. District Court for the District of Delaware entered a final judgment in its patent infringement lawsuit against Alcon over the Hydrus Microstent. The court upheld a jury’s findings that three Sight Sciences patents were valid and willfully infringed, awarding the company $55.4 million in damages covering past and supplemental damages plus interest.
The final judgment also granted Sight Sciences an ongoing 10% royalty on Hydrus revenue until the last of the asserted patents expires, potentially providing a meaningful long-term revenue stream. However, the ruling is subject to appeal, and Sight Sciences will not receive any damages unless appeals are resolved in its favor, while parallel reexamination proceedings at the Federal Circuit could still undermine its ability to collect on the award.
The most recent analyst rating on (SGHT) stock is a Hold with a $4.35 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.
Spark’s Take on SGHT Stock
According to Spark, TipRanks’ AI Analyst, SGHT is a Neutral.
The score is held down primarily by weak financial performance (persistent losses, ongoing cash burn, and equity erosion) and a bearish technical setup (price below key moving averages with negative MACD). Offsetting factors include constructive earnings-call momentum with improving profitability trends and FY2026 growth guidance, while valuation is difficult to support due to negative earnings and no dividend yield provided.
To see Spark’s full report on SGHT stock, click here.
More about Sight Sciences
Sight Sciences, Inc. operates in the medical device industry, focusing on ophthalmology technologies for the treatment of eye diseases. The company develops and commercializes products aimed at improving surgical outcomes and managing ocular conditions, positioning itself in the competitive market for innovative glaucoma and vision-care solutions.
Average Trading Volume: 297,821
Technical Sentiment Signal: Sell
Current Market Cap: $229.5M
See more data about SGHT stock on TipRanks’ Stock Analysis page.